Could a diabetes pill help lungs? new trial explores empagliflozin for PAH
NCT ID NCT06554301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether empagliflozin, a drug used for diabetes, can help people with pulmonary arterial hypertension (PAH). About 72 adults will take either the drug or a placebo daily for 12 weeks. Researchers will check if it lowers lung blood pressure and improves heart function, while also monitoring side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests
- Could a new drug free PAH patients from daily pump therapy?
- Could pedaling backward help heart and lung patients get stronger?
- New drug aims to help lungs and heart work better during exercise
- Heart scans could spare patients from invasive catheter procedures